Researchers collaborate on first-in-human study of novel malaria vaccine

May 31, 2017, Instituto de Medicina Molecular
P. berghei parasite multiplying inside a liver hepatocyte and presenting at the interface with the host cell, the major antigen, the circumsporozoite protein. Credit: Miguel Prudêncio lab, iMM Lisboa

An international research collaborative is testing a new approach to malaria vaccine development in humans for the first time. The concept is similar to that used by Edward Jenner to develop a vaccine against smallpox, the only disease affecting humans that has ever been eradicated. Jenner used cowpox, a much less dangerous bovine version of the disease, to inoculate people against smallpox. In this clinical trial, based on data from earlier animal studies conducted by iMM Lisboa, the researchers will use a rodent version of the malaria-causing parasite (Plasmodium berghei) to determine if it can induce protection against infection by Plasmodium falciparum, the deadliest version of the parasite that infects humans.

In the study, a specific gene from P. falciparum known as the circumsporozoite protein (CS), will be inserted into the rodent parasite, resulting in a genetically modified version known as Pb(PfCS@UIS4). By inserting the gene for CS, the researchers hope to improve the potential of the modified rodent parasite to induce a protective response in healthy human volunteers.

"Bringing together the concept underlying the first vaccine ever developed, combined with modern genetic manipulation tools, is a truly innovative approach to vaccination," said Miguel Prudêncio, who is leading the research team at iMM Lisboa.

The trial will be conducted in two phases at Radboudumc in the Netherlands. In the first phase, 18 healthy adult volunteers will be recruited into three groups and exposed to a varying, but carefully controlled number of bites from mosquitoes infected with the genetically modified P. berghei parasite. The researchers will closely monitor volunteers for signs of infection to make sure they are treated if they become ill. If all goes well in the Phase 1 study, volunteers from the highest dose group will enter the second phase of the study, which is designed to assess protective efficacy of the approach.

A P. berghei sporozoite (the infective Plasmodium parasite form injected by mosquitoes in the mammalian skin) sheds its major antigen, the circumsporozoite protein, during its gliding movement to reach a liver cell. Credit: Miguel Prudêncio lab, iMM Lisboa
"This is the first time we have tested a genetically modified malaria vaccine approach in Europe using this rodent parasite," said Robert Sauerwein, principal investigator and professor of medical parasitology at Radboudumc. "Along with our partners in the Netherlands, the Havenziekenhuis and Erasmus MC, we're looking forward to investigating whether this novel concept might one day contribute to the elimination and eradication of this terrible disease."

Malaria killed more than 429,000 people in 2015, most of them young African children. Although the most advanced vaccine in development globally is slated for pilot implementation in parts of Africa beginning in 2018—an incredible accomplishment and critically important step—researchers are still on the hunt for a malaria vaccine that can confer higher levels of durable efficacy. The long-term goal of the community, as outlined in the World Health Organization's Malaria Vaccine Technology Roadmap, is to develop vaccines with protective efficacy of at least 75 percent against clinical malaria, and vaccines that reduce transmission of the parasite in order to lower the incidence of .

"Although much progress has been made to drive down the malaria burden with currently available interventions, a highly effective would be an important new tool for ," said Ashley Birkett, director of PATH's Malaria Vaccine Initiative (MVI). "We are pleased to collaborate with Radboudumc and iMM Lisboa on testing this novel approach."

Explore further: Modified experimental vaccine protects monkeys from deadly malaria

Related Stories

Modified experimental vaccine protects monkeys from deadly malaria

May 22, 2017
Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, modified an experimental malaria vaccine and showed that it completely protected four of eight ...

Experimental vaccine protects against multiple malaria strains

February 20, 2017
An experimental malaria vaccine protected healthy subjects from infection with a malaria strain different from that contained in the vaccine, according to a study published today in the Proceedings of the National Academy ...

Malaria elimination: Vaccines should be tested on larger groups of volunteers

January 12, 2017
To find an effective vaccine against malaria it is crucial to test candidate vaccines on larger groups of people than previously thought - according to a new study published in PLOS Computational Biology. The researchers ...

Mosquito bites deliver potential new malaria vaccine

September 11, 2013
This study suggests that genetically engineered malaria parasites that are stunted through precise gene deletions (genetically attenuated parasites, or "GAP") could be used as a vaccine that protects against malaria infection. ...

Scientists devise novel way to predict efficacy of malaria vaccines

February 13, 2017
The acid test for a vaccine is: "Does it protect people from infection?" Emory Vaccine Center researchers have analyzed this issue for a leading malaria vaccine called RTS,S, and their results have identified candidate signatures, ...

Recommended for you

Synthetic DNA-delivered antibodies protect against Ebola in preclinical studies

November 13, 2018
Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. Study results, published ...

Scientists illuminate causes of hepatitis B virus-associated acute liver failure

November 13, 2018
National Institutes of Health scientists and their collaborators found that hepatitis B virus (HBV)-associated acute liver failure (ALF)—a rare condition that can turn fatal within days without liver transplantation—results ...

New strategy discovered toward possible prevention of cancers tied to mono, the 'kissing disease'

November 12, 2018
Researchers from the University of Minnesota, the Howard Hughes Medical Institute, and the University of Toronto have discovered a possible path forward in preventing the development of cancers tied to two viruses, including ...

Combination therapy promising against blindness-causing bacterial keratitis

November 12, 2018
Multidrug-resistant bacterial infections of the cornea are a leading cause of blindness and cannot be effectively managed with current ophthalmic antibiotics. A team of investigators has now devised a combination therapy ...

Hepatitis C treatment can be shortened in 50 percent of patients, study finds

November 12, 2018
Hepatitis C drugs cure more than 90 percent of patients, but can cost more than $50,000 per patient.

Salmonella found to be resistant to different classes of antibiotics

November 12, 2018
Brazil's Ministry of Health received reports of 11,524 outbreaks of foodborne diseases between 2000 and 2015, with 219,909 individuals falling sick and 167 dying from such diseases. Bacteria caused most outbreaks of such ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.